Expertise in
6
conditions

Dr. Alberto Broniscer

Pediatric Hematology Oncology
262 Danny Thomas Place, Ms 0515, St. Jude Children's Research Hospital, 
Memphis, TN 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
6
conditions
262 Danny Thomas Place, Ms 0515, St. Jude Children's Research Hospital, 
Memphis, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Alberto Broniscer is a Pediatric Hematologist Oncology provider in Memphis, Tennessee. Dr. Broniscer is highly rated in 6 conditions, according to our data. His top areas of expertise are Diffuse Midline Glioma H3 K27M-Mutant, Brain Stem Cancer, Glioma, and Medulloblastoma.

His clinical research consists of co-authoring 112 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in TN
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

262 Danny Thomas Place, Ms 0515, St. Jude Children's Research Hospital, Memphis, TN 38105

Additional Areas of Focus

Dr. Broniscer has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase II Study of Vaccinations with HLA-A2 Restricted Glioma Antigen Peptides in Combination with Poly-ICLC for Children with Recurrent Unresectable Low-Grade Gliomas (LGG)
A Phase II Study of Vaccinations with HLA-A2 Restricted Glioma Antigen Peptides in Combination with Poly-ICLC for Children with Recurrent Unresectable Low-Grade Gliomas (LGG)
Enrollment Status: Recruiting
Publish Date: January 06, 2025
Intervention Type: Biological
Study Phase: Phase 2
Immunotherapy for Recurrent Ependymomas in Children Using Human Leukocyte Antigen (HLA)-A2 Restricted Tumor Antigen Peptides in Combination with Imiquimod
Immunotherapy for Recurrent Ependymomas in Children Using Human Leukocyte Antigen (HLA)-A2 Restricted Tumor Antigen Peptides in Combination with Imiquimod
Enrollment Status: Recruiting
Publish Date: December 06, 2024
Intervention Type: Other, Biological, Drug
Study Drugs: HLA-A2 Restricted Synthetic Tumor Antigen, Imiquimod
Study Phase: Phase 1
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2025
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: Cisplatin, Cyclophosphamide, Lomustine, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 1
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Procedure, Drug
Study Drug: Savolitinib
Study Phase: Phase 1
Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT
Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Alisertib, Methotrexate, Cisplatin, Carboplatin, Cyclophosphamide, Etoposide, Topotecan, Vincristine
Study Phase: Phase 2
Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young Adults
Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib, Hydroxychloroquine
Study Phase: Phase 1/Phase 2
A Pilot Study to Evaluate the Effects of Vaccinations with HLA-A2-Restricted Glioma Antigen-Peptides with Poly-ICLC for Children with Newly Diagnosed Malignant Brain Stem Gliomas, Non-Brainstem High-Grade Gliomas, Recurrent Low-Grade Gliomas or Recurrent High Grade Gliomas
A Pilot Study to Evaluate the Effects of Vaccinations with HLA-A2-Restricted Glioma Antigen-Peptides with Poly-ICLC for Children with Newly Diagnosed Malignant Brain Stem Gliomas, Non-Brainstem High-Grade Gliomas, Recurrent Low-Grade Gliomas or Recurrent High Grade Gliomas
Enrollment Status: Completed
Publish Date: December 06, 2024
Intervention Type: Biological
Study Drugs: HLA-A2 Restricted Glioma Antigen Peptides Vaccine, Poly-ICLC
Study Phase: Phase 1
Phase 1 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
Phase 1 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
Enrollment Status: Completed
Publish Date: April 25, 2024
Intervention Type: Drug
Study Drug: LBH589
Study Phase: Phase 1
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Enrollment Status: Completed
Publish Date: December 13, 2023
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib, Carboplatin with Vincristine
Study Phase: Phase 2
A Phase 1b/2, Multicenter, Open-Label Study of Oral Infigratinib in Pediatric Subjects With Advanced Solid and Central Nervous System (CNS) Tumors (Phase 1b) and in Subjects With Recurrent or Progressive Low-Grade Gliomas Harboring Selected FGFR1, FGFR2, or FGFR3 Alterations (Phase 2)
A Phase 1b/2, Multicenter, Open-Label Study of Oral Infigratinib in Pediatric Subjects With Advanced Solid and Central Nervous System (CNS) Tumors (Phase 1b) and in Subjects With Recurrent or Progressive Low-Grade Gliomas Harboring Selected FGFR1, FGFR2, or FGFR3 Alterations (Phase 2)
Enrollment Status: Withdrawn
Publish Date: February 23, 2023
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Phase 1/Phase 2
Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors
Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors
Enrollment Status: Terminated
Publish Date: March 02, 2021
Intervention Type: Other, Drug
Study Phase: Phase 1
Phase II Study of Peginterferon Alfa-2b (Sylatron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma
Phase II Study of Peginterferon Alfa-2b (Sylatron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma
Enrollment Status: Terminated
Publish Date: February 24, 2020
Intervention Type: Other, Biological
Study Phase: Phase 2
Phase I Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Phase I Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Enrollment Status: Completed
Publish Date: March 22, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

112 Total Publications

The T cell receptor landscape of childhood brain tumors.
The T cell receptor landscape of childhood brain tumors.
Journal: Science translational medicine
Published: March 19, 2025
Similar Doctors
Expertise in
13
conditions
Dr. Amar J. Gajjar
Pediatric Hematology Oncology
Expertise in
13
conditions
Dr. Amar J. Gajjar
Pediatric Hematology Oncology
262 Danny Thomas Pl, 
Memphis, TN 
 (0.6 miles away)
901-595-3006
Languages Spoken:
English
See accepted insurances

Amar Gajjar is a Pediatric Hematologist Oncology provider in Memphis, Tennessee. Dr. Gajjar is highly rated in 13 conditions, according to our data. His top areas of expertise are Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, Diffuse Midline Glioma H3 K27M-Mutant, and Posterior Fossa Decompression.

Expertise in
14
conditions
Dr. Marcin W. Wlodarski
Pediatric Hematology Oncology
Expertise in
14
conditions
Dr. Marcin W. Wlodarski
Pediatric Hematology Oncology
262 Danny Thomas Pl, 
Memphis, TN 
 (0.6 miles away)
888-226-4343
Languages Spoken:
English
See accepted insurances

Marcin Wlodarski is a Pediatric Hematologist Oncology provider in Memphis, Tennessee. Dr. Wlodarski is highly rated in 14 conditions, according to our data. His top areas of expertise are Aase Syndrome, Pure Red Cell Aplasia, Dyskeratosis Congenita, Bone Marrow Transplant, and Splenectomy.

Expertise in
8
conditions
Dr. Deepa Manwani
Pediatric Hematology Oncology
Expertise in
8
conditions
Dr. Deepa Manwani
Pediatric Hematology Oncology
262 Danny Thomas Pl, 
Memphis, TN 
 (0.6 miles away)
901-595-3300
Languages Spoken:
English
See accepted insurances

Deepa Manwani is a Pediatric Hematologist Oncology provider in Memphis, Tennessee. Dr. Manwani is highly rated in 8 conditions, according to our data. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Splenectomy, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Broniscer's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile